|Articles|December 3, 2012

AHIP's Fall Forum 2012 Slideshow

Check out photos from America's Health Insurance Plans Fall Forum 2012. The meeting is being held at the Renaissance Hotel in Chicago, IL, from December 3-5.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Patient and caregiver | Image Credit: © manassanant -stock.adobe.com

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

ByMaggie L. Shaw

June 26th 2026

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 25th 2026

Dr Claire Harrison | Image Credit: Guy's and St. Thomas' NHS Foundation Trust

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

ByBrooke McCormick,Claire Harrison, MD

June 25th 2026

Acuteleukemiawordcloud | Image Credit: © ibreakstock-stock.adobe.com

Venetoclax Combinations Show Promise Across ALL/AML

ByMaggie L. Shaw

June 25th 2026

AHIP's Fall Forum 2012 Slideshow

Related Content

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

Venetoclax Combinations Show Promise Across ALL/AML

Trending on AJMC

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

House Panel Advances Bills to Expand Veterans’ Health Care Access

House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden

The Oncology Care Model: A Decade of Transformation

Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

AHIP's Fall Forum 2012 Slideshow

Related Content

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

Venetoclax Combinations Show Promise Across ALL/AML

Trending on AJMC

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

House Panel Advances Bills to Expand Veterans’ Health Care Access

House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden

The Oncology Care Model: A Decade of Transformation

Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant